The Most Controversial Paper in the History of Psychedelic Research May Never See the Light of Day
Rick Doblin had come to believe that psychedelic experiences are the "common core" of all religions, and he wanted to test this thesis. In February 1984, the 31-year-old college student living off a trust fund in Sarasota, Florida, typed out a letter to the United Nations, proposing a study that would double as a "training program for a variety of religious ministries." He needed only 50 volunteers, he said, plus a panel of scholars and religious mystics (including His Holiness the Dalai Lama) to judge the results.
Doblin reached out to several politicians for help too. He even wrote a letter to Pope John Paul II. In the meantime, he took on what might have been an even more daunting task, though today it sounds almost mainstream: turning MDMA into medicine.
Beginning in 2015, another psychedelic visionary, Roland Griffiths, initiated a research project nearly identical to what Doblin envisioned. A collaboration between the Johns Hopkins University School of Medicine and NYU Langone Health, Griffiths' experiment gave psilocybin to two dozen "religious professionals"—Christian, Jewish, Buddhist, and Muslim clergy—on two separate occasions.
What happened is still mostly a mystery, as the paper has yet to be released. Just as the finishing touches were being finalized, Griffiths was diagnosed with Stage 4 cancer. At the same time, a controversy was growing in his lab that threatened to derail the psychedelic renaissance. The accusations centered on alleged misconduct involving the religious professionals study.
Five months after Griffiths died peacefully at his home in October 2023, The New York Times published a bombshell exposé that called the study's integrity into question. The article drew on two ethics complaints filed by a former protégé, a psychologist named Matthew Johnson whom Griffiths had groomed to be his replacement.
Griffiths, Johnson said, had been running his research lab less like a laboratory and more like a "'new-age' retreat center," recommending spiritual literature to volunteers and allowing politically aligned funders to work directly on studies. These funders were also paying for projects aimed at introducing various religious communities to hallucinogens. The line between research and advocacy, he argued, had disappeared.
Johnson also accused Griffiths of infusing his research with his own spiritual beliefs and advancing a political agenda aimed at spreading the use of psychedelics. All this, Johnson said, created a "cult-like atmosphere."
The release of the religious professionals study was put on a permanent hiatus. Since then, more information has emerged about Griffiths and the researchers around him, shedding light on an ambitious plan to revitalize Christianity by incorporating a psychedelic sacrament.
Doblin, who is now the president of the Multidisciplinary Association for Psychedelic Studies, thinks the unreleased study might be the most important research paper in psychedelic history. It will be a "terrible, terrible tragedy" if it is never released, he says. "I felt that it had the greatest political implications." He blames the delay in publication on fears "that it might spark a fundamentalist backlash against psychedelic research."
But the paper itself, he adds, doesn't "speak to this whole issue of the common mystical core. They avoid the kind of political benefits that I think could come from this understanding that religions are like languages. We all speak different languages but they're coming from the same basic source."
This idea—that there is one truth and one universal core to all religions—is the heart of Perennialism, a school of mysticism with a long history. Doblin is not the only person in the psychedelic world who is fascinated with this concept: It has turned up, well, perennially, in numerous scientific papers as well as a dubious but popular recent book called The Immortality Key. The idea's influence raises an important question about the renaissance of psychedelic studies: Are these researchers guided by science, religion, or some awkward combination?
Roland Redmond Griffiths was the avatar of a new generation of straitlaced scientists said to be bringing fresh blood, rigorous standards, and a cautious approach to an area of research tarnished by political antics and reckless evangelism. The scion of the same blue-blood family that produced President Franklin Delano Roosevelt, Griffiths was the psychedelic counterculture's dream spokesman: a clean-cut "scientist's scientist," so conservative that he once admonished the soft drink industry for "being in denial about the role of caffeine in their products."
Griffiths' career path took a left-hand turn when he was introduced to meditation and psychedelics. Bored with his research on opioids and tobacco, he started meditating regularly in the early '90s with a girlfriend who was a part of the new age scene. ("She believed a bunch of stuff I didn't believe," he later told me.) After a weeklong retreat, he found himself intrigued by the revelatory insights occasioned by mystical states of consciousness. When he was recruited by a sect called the Council on Spiritual Practices—the group's members have included Jordan Peterson, Ralph Hood, Willis Harman, Walter Houston Clark, and other psychologists interested in comparative mythology—Griffiths became the public face of an ambitious project to "make the mystical experience more available."
After reading works on Jungian psychology, Christian mysticism, and Perennialism, Griffiths slowly began to abandon his earlier commitment to the beliefs of B.F. Skinner, a psychologist who taught that behavior could be altered only through modification of the external environment. He started exploring the internal transformations described in the world's esoteric literature, and the life-altering "conversion" experiences described in the New Testament and other holy books.
These texts, along with the works of Harvard psychologist William James, suggested to Griffiths that an unknown biological energy—perhaps entering through the "subliminal trap door of the mind"—might be responsible for these experiences. If scientists could study them systematically in a lab, they might be able to isolate this force, analyze it, and harness its therapeutic benefits. What if science could cultivate trance states via psychoactive plants, sensory isolation, and music, reducing spiritual enlightenment to a systematic process easily accessible to all?
A 2006 press release from Johns Hopkins' media team—headlined "Hopkins Scientists Show Hallucinogen In Mushrooms Creates Universal 'Mystical' Experience"—captured Griffiths' mood. Acknowledging what he called the "unusual nature" of his research, Griffiths preempted any suspicion that science might be probing into the sacred domain. "We're just measuring what can be observed," Griffiths said. "We're not entering into 'Does God exist or not exist.' This work can't and won't go there." A Q&A attached to the press release expanded on this concern, assuring the scientific community that this "God pill" was notgoing to replace religion.
Doblin believes that the spiritual and medical aspects of psychedelics are so closely entangled that they're impossible to separate. Because Griffiths' primary finding was a link between religious experience and marked increases in well-being, the religious connotations of his work cannot be avoided. In fact, Doblin says, studies into the therapeutic benefits of psychedelics have all been "leading up towards" the religious leaders study. The psychedelic movement, he believes, is the vehicle for a "transformation in consciousness that humanity needs to make," one he compares to the "Copernican-Galileo revolution."
While Griffiths and Doblin frequently argued over strategy, their core beliefs were similar. Both were convinced that psychedelics are critical to the survival of the human species, a tool that can be used to "awaken" humanity to impending ecological catastrophe or nuclear war.
"It is a way to spiritualize people en masse, but starting with people in religious traditions," Doblin says. "This is why I felt that Roland's study—the religious leader study—had the most important political implications of all of the psychedelic research."
The Perennialist ideas in Griffiths' research are drawn from Forgotten Truth, a book published in 1976. Written by a religious studies professor named Huston Smith, the author was a disciple of a little-known Swiss writer named Frithjof Schuon who, in the 1980s, led a Sufi order based in Bloomington, Indiana.
Though Aldous Huxley was more widely read, Schuon crystallized an "intellectual version" of Perennialism that permeated the psychedelic literature, says Hugh Urban, a scholar of new religious movements at Ohio State University. "Forgotten Truth is where Smith articulates his version of Perennialism most clearly. And that book is just Schuon for the public."
Blending the teachings of the Oglala Lakota medicine man Black Elk with Christian imagery and hardline Islamic mysticism, Schuon taught his followers that the further civilization drifted from the one eternal truth, the more intensely it would descend into chaos and disorder. The ultimate goal of history, he said, was the uncovering of the transcendent unity of all religions and a "New World Order" of which he was the prophet and avatar.
Schuon's group attracted unwanted attention when the eccentric guru was accused of using his authority to satisfy his carnal desires, and it disbanded in 1991.
"Schuon's basic philosophy," Urban says, "is that there's one truth, one universal core to all religions. And at the outer level, the exoteric, all religions are very different, but the closer you get to the inner core, the closer they come. So from his perspective, you could blend them together because the closer you get to this universal truth, the more similar they become." Urban thinks Perennialism appeals to psychedelic enthusiasts because it suggests that "one can tap into the same universal Truth known to the mystics of all ages simply by taking a drug and without the need for the trappings of institutional religion."
Not everyone involved with the study subscribes to such beliefs. Johnson, the former protégé who filed the ethics complaints, thinks the findings have been exaggerated and taken out of context. "Some people want to see the results as validating the Perennial Philosophy," he says. "But it can't."
"I really don't agree that the implications are especially profound," he adds. "Religious professionals who are willing to participate in a psychedelic study tend to respond like others. A solid and publishable finding, but nothing too surprising. I think there was too much of a push to frame this as a magnum opus and a breakthrough on the spiritual effects of psychedelics."
Johnson has warned his colleagues of conflating religion and science. Like any other spiritual tradition where certain individuals—be it gurus, priests, or yogis—claim to have direct access to God, he argues, you are setting up a potentially dangerous situation: "Don't be surprised when you get the sexual abuse of minors or whoever else because of that sacred power."
Griffiths, on the other hand, was convinced that he made a groundbreaking scientific discovery with enormous cultural implications. His involvement with activity outside the scope of his official research included a "Holy Meeting" at the Vatican where one of his associates—a lawyer named Brian Muraresku—presented Pope Francis with a manifesto for a psychedelic "New Reformation."
The scientists conducting the religious professionals study discussed details of the meeting through text messages, which included a watermarked photograph of Muraresku—part of the inner circle of Hopkins researchers—preparing to hand the pope a copy of his 2020 book The Immortality Key, which argues that psychedelics might rescue a "dying faith" and save Western civilization. The book also claims that Christianity began as a spinoff of pagan mystery cults that used a hallucinogenic fungus in their most sacred ritual, which purportedly evolved into the Christian ceremony of communion. (Many people depicted in this supposedly "groundbreaking" book on psychedelics and religion are now speaking out against it. More on that here.)
While it's not clear whether the pope has actually read Muraresku's book, the Vatican did recently host a conference featuring a talk on psychedelic science. In September, a controversy broke out when Pope Francis expressed an idea akin to Perennialism: "Every religion," he said, "is a way to arrive at God."
Behind the scenes of the study, Muraresku was also involved with Ligare, a Christian missionary organization launched by a Hopkins clinical trial participant named Hunt Priest—a pastor and former Delta Airlines marketing executive—focused on introducing various Christian communities to psychedelics.
Since the investigation, there has been a notable silence from Griffiths' inner circle, though Hopkins has cut several of his core team members loose.
One of those who departed—Bill Richards—wrote the original protocol for the religious professionals' study and was Griffiths' right-hand man for many years. The 84-year-old psychologist claims to be unaware of what the investigation was really about. The paper, he insists, simply indicates that professional religious leaders can have religious experiences that are helpful to them. "What's the big deal about that? Why should that be controversial? I just don't understand it."
People from different spiritual traditions around the world, he says, "all report this unitive mystical consciousness."
"I'm convinced it's just part of our makeup, that within us is this great unity. And of course, within the unity is intuitive knowledge. And part of the unity of that knowledge is what the Hindus call the bejeweled Net of Indra, or the Unity of Mankind, or that everyone is ultimately connected to everyone else, which has profound implications for ethics and world peace, you know?"
Griffiths' problems with his subordinates, according to Richards, mainly centered on issues of control. "As much as I love and appreciate Roland, I would say he did have his blind spots, and I think he had difficulty empowering others. He could be very devaluing of the clinical dimension and very preoccupied with the statistics. Those numbers made him excited." According to Richards, his friend would be there all by himself on Saturdays, completely absorbed in his work, an aloofness that caused problems in earlier marriages. "Roland was working hard to get the last studies published and so on, almost up until he entered a coma. He was preoccupied with the most pedantic little details of manuscripts."
Though the two have been criticized for infusing scientific research with their own Perennialist beliefs, placing religious objects in the session rooms, and blessing participants with greetings of "namaste," Richards is unapologetic (people in India say namaste "on the street constantly," he objects) and stands behind the religious implications of his and Griffiths' work.
"I think we are participating in an expansion of consciousness, a spiritual awakening, an evolution of what we call normal," he says. There is no way to separate psychedelic therapy from its spiritual nature nor from the reality of our interconnectedness, he argues. He also suggests that the Food and Drug Administration incorporate philosophers and scholars of comparative religion into their advisory panels.
Richards also told me that Sacred Knowledge—his semi-autobiographical book, which doubles as a Perennialist manifesto—has now been translated into 10 languages. He also claimed that Muraresku had "smuggled 10 copies" of the book into the Vatican. Muraresku, who by Richards' account "just appeared in my backyard one day," is "a wonderful guy," Richards says. "He looks like this uptight conventional lawyer in the daytime and turns into Indiana Jones at night."
Ralph Hood, a psychologist who belongs to the Council on Spiritual Practices, also thinks that the controversy has been oversimplified and misinterpreted by people with no personal experience with psychedelics. The world's preeminent scholar of Appalachian serpent handling sects, Hood created a measurement scale that was widely used in psychedelic research; he also helped launch the studies at Johns Hopkins.
Hood, who at 82 is still teaching at the University of Tennessee at Chattanooga, has been criticized for importing Perennialism into psychedelic research. He denies that, and he also rejects the idea that Griffiths was infusing spiritual beliefs into his research. To the contrary, Hood says, the chief problem with psychedelic research is that the people studying mystical experiences "exclude the possibility that these are genuine spiritual phenomena."
There is a problematic and unquestioned assumption built into science, Hood says: the idea that the experience of transcendent and alternate realities is either delusional or proof of mental illness. What if there is, beyond the capability of the human senses, an "invisible order" that science cannot penetrate? These discriminatory attitudes—an unwarranted bias against religion—preclude the possibility of real innovation, rendering psychedelic research a futile endeavor. Griffiths, following in the footsteps of William James, remained open to these possibilities, leading some to accuse him of dabbling in occultism.
"William James fought back against the licensure of the professions. They're used to exclude, he said, not to include. So they give you a more restricted range of options, not the broader range that we need."
To make psychedelics a mainstream medicine, Hood argues, regulators are seeking a safety that will miscategorize psychedelics as antidepressants and destroy innovation. "The culture is looking for a type of safety that is actually life threatening," he says, "because it doesn't allow you to do what's really important in the long run. So the safe option is very often the worst option….You're not going to fall off the bike if you refuse to ever ride one."
The voices of the volunteers themselves, he adds, are being "effectively silenced" when they are told their experiences are not true. "It's extremely limiting and focused on one aspect of something and therefore falsifies the reality of phenomena."
In the wake of the controversy surrounding the religious professionals study, some scientists are shying away from the mystical experience construct—part of an effort to purge their work of Perennialist influences and distance themselves from anything that feels new age. By backing away from the Jamesian tradition, Hood argues, they're shooting themselves in the foot.
Hood is generally hopeful about the future of psychedelic research. "The danger," he says, "is it's going to be turned into a money-making machine, because the access to sacraments is going to be through prescription and then through pharmacies, and that's going to be a huge failure."
I am skeptical that researchers will offer a purely scientific explanation for the mystical experience anytime soon, as current methods hardly begin to reveal the hidden mechanics behind the bizarre episodes that people like Hood and Griffiths study. For what it's worth, Griffiths felt the same way. "Reductionistic materialists would say, well, this ultimately boils down to brain network changes," Griffiths told me in 2023. "But the level of complexity there far outstrips anything that we can possibly measure. So we're at our infancy in terms of understanding the neuroscience. Our ability to measure what's going on in the brain is incredibly primitive….All we can do is start guessing at it, and then using different frames of reference to explain it."
And what about Doblin, the man who dreamed four decades ago of something like Griffiths' study? That experiment, he says, is the very last thing that he and Griffiths discussed before the latter's death. By Doblin's account, Griffiths had had a change of heart about their strategic disagreements and recognized his approach as overly cautious.
"He said, 'You were more right than I was about the importance of drug policy reform, and I was too conservative to object to these things,'" Doblin recounts. "I feel like he had come to see that it's about changing culture as well as doing the science. If you don't change the culture, then you can't even do the science."
Ever the visionary, the 71-year-old Doblin is still looking for opportunities to merge religion and medicine. On a recent trip to Spain, an incense holder suspended from an enormous dome with ropes in the Cathedral of Santiago caught his eye. "And they could swing this incense holder to spread it throughout the church. But, I said, it was inactive wafers. So I think distributing these things through religion would be a really good idea if people were encouraged to really explore more, to tap into this Perennial philosophy."
I asked him whether he would attempt to resurrect his U.N. proposal from 1984. He smiled and said no. "I think we're too wrapped up in trying to make MDMA into a medicine to see what that involves."
The post The Most Controversial Paper in the History of Psychedelic Research May Never See the Light of Day appeared first on Reason.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Psychedelic Science 2025 Unveils Science, Studies & Trials Tracks Showcasing Next Generation in Brain Imaging, Clinical Trials, and Neuroplasticity
• Sessions cover the latest updates in psychedelic neuroscience, from psilocybin's effects on brain connectivity to trial design, clinical outcomes for PTSD, depression, addiction, and OCD, and the future of drug development through translational models and AI innovations • Speakers include globally renowned experts like Gabrielle Agin-Liebes, Ph.D., Michael Bogenschutz, M.D., Robin Carhart-Harris, Ph.D., Alan K. Davis, Ph.D., Gül Dölen, M.D., Ph.D., Ben Kelmendi, M.D., Franklin King, M.D., Amy Lehrner, Ph.D., Leslie Morland, Psy.D., David Nutt, Ph.D., Stephen Ross, M.D., Emmanuelle Schindler, M.D., Ph.D., and Nolan Williams, M.D. • Representing institutions include Columbia, CU Denver, Imperial College London, Johns Hopkins, LSU, Massachusetts General Hospital, NYU, Ohio State, Stanford, UC Berkeley, UCSD, UCSF, University of Alabama, University of New Mexico, University of Washington, and numerous VA centers DENVER, June 11, 2025 (GLOBE NEWSWIRE) -- Psychedelic Science 2025 (PS2025), the world's leading conference on psychedelic research, medicine, policy, and culture hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), announced its Science, Studies, and Trials tracks—three of the conference's most anticipated and data-rich offerings. Taking place June 16–20, 2025, at the Colorado Convention Center in Denver, PS2025's research tracks will convene top clinical investigators, neuroscientists, biotech pioneers, and social scientists to present a comprehensive and cross-disciplinary view of this transformative field of study. At a time when the global mental health crisis continues to grow, PS2025 showcases therapeutic research using psychedelic compounds such as psilocybin, MDMA, LSD, DMT, 5-MeO-DMT, and ketamine, which are being investigated as treatments for serious mental illnesses such as addiction, depression, PTSD, obsessive-compulsive disorder, as well as neurological conditions such as pain, Alzheimer's, Lyme Disease, and Parkinson's. Beyond clinical trials, PS2025 also offers the latest in psychedelic neuroscience, examining data from studies using new neuroimaging, cellular, and molecular research tools that deepen the understanding of the biological mechanisms underlying their remarkable effects. Social science research is also included that examines the usage, attitudes, and experiences of trial participants, psychedelic consumers, and the general public, providing important context for societal views about this rapidly growing field. 'With the science and understanding of psychedelic substances expanding exponentially in recent years, we're honored to welcome some of the world's top academic researchers to PS2025 so they can share this new knowledge with attendees from around the globe.'— Philippe Lucas, Ph.D., Director, Research & Safe Access, MAPS The Science, Studies, and Trials tracks will feature both senior research leaders as well as emerging voices from public and private universities throughout North America, as well as international institutions in the UK, Europe, and Latin America. This highly anticipated convergence allows scientists to engage deeply about hot topics, including durability of efficacy, safety and risk, placebo dynamics, the role of psychotherapy, transdiagnostic effects, precision psychiatry, biological mechanisms, novel compounds, and the role of government grants and private capital in innovation. Visit to view the full schedule, register for workshops, and explore hotel and travel options. Workshop spaces are limited and available on a first-come basis. Featured sessions in the Science, Studies, and Trials tracks include:20 Years of Human Neuroscience Research with PsychedelicsDavid Nutt, Ph.D., reflects on two decades of pioneering work using brain imaging and neuropharmacology to explore consciousness, depression, and psychedelic mechanisms of action. Psychedelic Frontiers at the National Institutes of Health: NIH-funded Studies, Research Opportunities, and PrioritiesJoin a conversation moderated by Stacy Fischer, M.D., featuring Michael Bogenschutz, M.D., and Patrick Finan, Ph.D., as they unpack the latest NIH-funded studies, explore future research opportunities, and discuss the evolving priorities shaping this rapidly growing field of psychedelic-assisted therapy. Frontiers in Psilocybin Research for OCD: Neural Mechanisms, Treatment Response, and Clinical ImplicationsIn a session moderated by Jamila Hokanson, M.D., Ben Kelmendi, M.D., and Terence Ching, Ph.D., explore cutting-edge research on psilocybin's neural effects, clinical outcomes, and its potential as a treatment for OCD. Studies of Psychedelic-Assisted Therapy for Addiction DisordersJoin a conversation with Matthew Johnson, Ph.D., and Rayyan Zafar, Ph.D., moderated by Peter Hendricks, Ph.D., for a discussion on the latest research into the use of psychedelics as tools to treat addiction. This session will explore emerging evidence, clinical insights, and the challenges and promises of integrating psychedelic-assisted therapy into addiction treatment frameworks. Psychedelic Therapy for Military Veterans: A New Paradigm of Healing the Wounds of WarModerated by Chris Stauffer, M.D., and featuring Allie Kaigle, PharmD, BCPP, Amy Lehrner, Ph.D., and Leslie Morland, Psy.D., this session examines how psychedelic-assisted therapies are reshaping the landscape of care for Veterans grappling with PTSD, depression, and moral injury. By combining cutting-edge research with lived experience, these experts reveal how these innovative therapies can unlock hope, resilience, and lasting healing for those who have Outcomes from a Trial of Psilocybin-Assisted Therapy for Major Depressive DisorderIn this presentation, Alan K. Davis, Ph.D., shares groundbreaking findings from a long-term follow-up study examining the sustained effects of psilocybin-assisted therapy for individuals with major depressive disorder and what these results mean for the future of psychedelic treatments in mental health care. Ayahuasca: Bridging Molecular and Clinical Insights – A Multidisciplinary PanelDráulio Araújo, Ph.D., moderates a conversation with Fernanda Palhano-Fontes, Ph.D., Marcelo Falchi Parra Carvalho Silva, M.D., and Marcelo Leite, Ph.D., on the multifaceted world of ayahuasca through a unique convergence of molecular research, clinical practice, and traditional wisdom. The conversation offers insights into ayahuasca's molecular mechanisms and its applications in healing trauma and supporting personal growth. Developing Ibogaine for Opioid Use Disorder: Bridging Science, Public Benefit, and Sacred RootsSusan Ousterman moderates a conversation with Jeremy Weate, Ph.D., Ryan Rich, and Peter Hendricks, Ph.D., on the journey of ibogaine from traditional medicine to modern addiction therapy. Together, they'll explore clinical advancements, regulatory challenges, and how to ethically integrate indigenous knowledge and practices to address the opioid epidemic. Improving Standardization and Reducing Bias in Psychedelic Drug Development Trials Using an AI-Enabled PlatformJennifer Tippett, Psy.D., and Danielle Schlosser, Ph.D., discuss how artificial intelligence can transform psychedelic research by improving standardization, reducing bias, and enhancing data quality in clinical trials. Discover how this innovative approach is shaping the next generation of rigorous, ethical, and effective psychedelic drug development. The Potential for Psychedelic-Assisted Therapy in Conflict-Affected Populations: Ukraine and the BalkansModerated by Tadeusz Hawrot and featuring Oksana Gryshchenko, Elise Wilson, Zina Besirevic, Ph.D., and Galyna Pidpruzhnykova, Ph.D., this panel explores how psychedelic-assisted therapies might offer pathways to healing for individuals and communities affected by war and Differences in Therapeutic Outcomes Between Synthetic Psilocybin and Whole Psilocybe Mushrooms: A Qualitative StudyJoin Pamela Kryskow, M.D., and Joseph La Torre, Ph.D., as they present their qualitative study exploring the participants' lived experiences and perceptions, offering a deeper understanding of how these distinct forms of psilocybin influence healing, integration, and personal transformation. The Unique Challenges and Potential for Studying Psychedelic-Assisted Therapy for Palestinians and Jews in IsraelModerated by Keren Tzarfaty, Ph.D., MFT, and featuring Adar Avnon, Sidi Ronen, Ph.D., and Clinical Psychologist Wasim Biroumi, this session dives into the promise and complexities of researching psychedelic-assisted therapy in the unique socio-political landscape of Israel. The panel will discuss how shared trauma and cultural dynamics shape therapeutic approaches and the role psychedelics may play in fostering healing, understanding, and resilience across Outcomes from Yale's Real-World Psilocybin Trial: Connecticut-Funded Pioneering Psychedelic Therapy Program and Insights from Other State InitiativesJesse MacLachlan and Gabrielle Agin-Liebes, Ph.D., share findings from Yale's groundbreaking psilocybin trial, the first state-funded psychedelic therapy program in the U.S. This session will examine the transdiagnostic benefits observed in real-world settings and highlight key insights from Connecticut's initiative alongside other state-led programs shaping the future of psychedelic-assisted Critical Periods and Cephalopods: A Conversation with Neuroscientist Dr. Gül DölenJoin Gül Dölen, M.D., Ph.D., and Amy Emerson for a fascinating conversation that spans critical periods in brain development and the remarkable learning abilities of cephalopods. This session will illuminate the connections between these insights and the potential of psychedelics to re-open windows of plasticity in the adult brain. Listening to Lead: How a Community-Informed Psilocybin Study is Guiding New Mexico's Regulated ModelCrystal Romero, Janus Herrera, Dara Menashi, Ph.D., Larry Leeman, M.D., and Hanifa Nayo Washington (moderator) explore how New Mexico's historic Senate Bill 219 is paving the way for the nation's first state-regulated medical psilocybin program. This panel spotlights the community-informed pilot study by the Psychedelic Health Equity Initiative (PHEI), designed to center equity, accessibility, and culturally attuned care for underserved communities. Expanding the Lens: Mechanisms, Models & Modes - Transdiagnostic Potential of Psychedelic MedicinesJoin Charles Nichols, Ph.D., and Robin Carhart-Harris, Ph.D., as they unpack the unique mechanisms and models of action that position psychedelics as potential transdiagnostic treatments by addressing shared root causes across conditions. Treating Care Providers and Long COVID with Psychedelic-Assisted TherapyAnthony Back, M.D., moderates a vital discussion with Lawrence Purpura, M.D., Ph.D., Benjamin Lewis, M.D., Kush Bhatt, M.D., and Saleena Subaiya, M.D., on the emerging promise of psychedelic-assisted therapy to help those suffering from long COVID and the burnout experienced by care providers. This session will share clinical updates, innovative approaches, and new possibilities for fostering healing for those on the front lines of care. A Machine Learning Perspective on Psychedelics and PsychopathologyArthur Juliani, Ph.D., shares how artificial intelligence is revolutionizing clinical trial design, protocol optimization, and predictive modeling for psychedelic studies. From Rodents to Humans: Unlocking the Science of Psychedelic-Induced NeuroplasticityModerated by Lindsay Cameron, Ph.D., and featuring Manesh Girn, Ph.D., Max Vargas, Ph.D., and Neil Savalia, M.D./Ph.D(c), this session investigates the limitations of preclinical models in capturing the complexity of human psychedelic experiences and what these challenges mean for the future of psychedelic drug development. Psilocybin Desynchronizes the Human BrainJoin Joshua Siegel, M.D., Ph.D., as he delves into cutting-edge research exploring how psilocybin disrupts established patterns of brain connectivity – unpacking how these transient states of neural desynchronization might illuminate new pathways for therapeutic breakthroughs, and revealing the brain's remarkable flexibility and potential for healing. About Psychedelic SciencePsychedelic Science 2025 (PS2025), hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), is the world's leading psychedelic conference. Returning to the Colorado Convention Center in Denver from June 16-20, 2025, this five-day event brings together a global community of scientists, therapists, policymakers, cultural leaders, and advocates to explore the forefront of psychedelic research, therapy, and culture. Facilitated by Superfly, known for producing iconic events such as Bonnaroo and Outside Lands, PS2025 will feature expert speakers; hands-on workshops; community events with art, music, and mindfulness activities; and scholarship opportunities to support broad participation. Since its inception in 2010, the Psychedelic Science conference series has fostered knowledge-sharing, collaboration, and community-building within the psychedelic ecosystem. Join thousands of attendees as we explore the transformative potential of psychedelics and shape the future of mental health, policy, and cultural understanding. For more information and registration details, visit and follow us on X, Instagram, LinkedIn, and Facebook. ABOUT MAPSFounded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS' conference flagship, Psychedelic Science, has been the leading convening of the psychedelic community since 2010. MAPS incubated Lykos Therapeutics, a drug-development public benefit company, and the Zendo Project, a leader in psychedelic harm reduction. Since MAPS was founded, philanthropic donors and grantors have given more than $150 million to advance research, change drug policy, and evolve education in the field of psychedelics. CONTACTmedia@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
11 hours ago
- Yahoo
A Study Says Gray Hair May Be Reversible
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." A study links graying hair to stem cells getting stuck, unable to color new hair growth. Stem cells travel back and forth within compartments, but when they get stuck in one compartment, they cannot regenerate into pigment cells. Restoring mobility of the cells could allow the continuation of pigment production, eliminating graying hair. If only our pesky stem cells didn't get stuck in place after a while, maybe we wouldn't have gray hair. Really. In a study published in the journal Nature, researchers from New York University's Grossman School of Medicine revealed how stuck melanocyte stem cells (McSCs) can't make the protein needed to pigment hair, potentially explaining gray hair. Using mice as the research subjects, the team found that McSCs travel between compartments of developing hair follicles in a healthy situation. The differing compartments allow the McSCs to mature and pick up the protein that can regenerate into pigment cells and continually color hair as it grows. These McSCs shift back and forth between maturity levels over time as they continually move between the compartments, a unique aspect of the McSCs. But in some cases, the McSCs can get stuck in the hair follicle bulge compartment and become unable to move back to the germ compartment, where the WNT proteins encourage the cells to regenerate into pigment cells. Getting stuck means no pigment cells, which means gray hair. 'It is the loss of chameleon-like function in melanocyte stems cells that may be responsible for graying and loss of hair color,' Mayumi Ito, study senior investigator and professor in the Ronald O. Perelman Department of Dermatology and Department of Cell Biology at NYU Langone Health, says in a news release. 'These findings suggest that melanocyte stem cell motility and reversible differentiation are key to keeping hair healthy and colored.' Basically, if the McSCs can keep moving—or, if they get stuck, we can somehow prod them to get going again—we should expect more colorful heads of hair the world over. 'Our study adds to our basic understanding of how melanocyte stem cells work to color hair,' Qi Sun, postdoctoral fellow at NYU Langone Health, says in the release. 'The newfound mechanisms raise the possibility that the same fixed positioning of melanocyte stem cells may exist in humans. If so, it presents a potential pathway for reversing or preventing the graying of human hair by helping jammed cells to move again between developing hair follicle compartments.' The McSCs focus on pigment-making, and are different from cells responsible for hair growth, Sun says, so hair can to continue growing even without pigment. The NYU study showed that as the hair regrowth process aged, the number of McSC's lodged in the follicle bulge continued to increase. At some points, this non-pigment producing follicle bulge contains roughly 50 percent of all McSCs. The McSCs that remained mobile retained their ability to produce pigment, but with the ever-shifting requirements of McSCs breaking down over time, the rise of gray hair coincided with aging. And while stress has also been associated with graying hair, unrelated Harvard research says that stress simply increases the hair regrowth pattern, speeding up the aging process for hair follicles. 'For unknown reasons, the melanocyte stem cell system fails earlier than other adult stem cell populations, which leads to hair graying in most humans and mice,' according to the NYU study. The next step for the NYU team involves looking at how we can get McSCs, once stuck, moving again. Because once they move, they create pigment. And that could mean the end of gray. You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?
Yahoo
14 hours ago
- Yahoo
Home Healthcare Market Share Worth $666.91 billion, Globally, by 2030 - Exclusive Study by The Research Insights
CHICAGO, June 11, 2025 /PRNewswire/ -- The Global Home Healthcare Market share is projected to be valued at USD 420.79 billion in 2024 and reach USD 666.91 billion by 2030, growing at a CAGR of 7.96% according to a new report by The Research Insights. The rise of cost-effective alternatives to address increasing healthcare costs has driven this growth. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the Home Healthcare Market growth of 7.96% comprises a vast array of Component, Indication and Geography which are expected to register strength during the coming years. For More Information and To Stay Updated on The Latest Developments in The Global Home Healthcare Market Size, Download FREE Sample Pages: Market Overview and Growth Trajectory: Home Healthcare Market Growth: According to an exhaustive report by The Research Insights, the Home Healthcare Market is experiencing significant growth. The global home healthcare market is experiencing robust growth, driven by a confluence of emerging and evolving factors. A major driving force is the global demographic shift toward an aging population, particularly in developed economies, which is significantly increasing the demand for chronic disease management and age-related care within the comfort of patients' homes. Simultaneously, the rising prevalence of chronic conditions such as diabetes, cardiovascular disorders, and respiratory diseases is fueling the need for accessible and cost-effective home-based solutions. Technological advancements—such as AI-enabled remote monitoring, wearable health devices, and smart home integration—are transforming home healthcare delivery by enhancing real-time diagnostics, personalized care, and patient engagement. Additionally, the growing acceptance and adoption of telehealth services, accelerated by the COVID-19 pandemic, have normalized virtual care models, making them an integral part of home healthcare ecosystems. Market expansion is further supported by increased healthcare expenditures, shifting consumer preferences toward convenience, and supportive government policies and reimbursement frameworks. Moreover, the emergence of platform-based home healthcare services, supported by big data analytics and cloud computing, is enabling better coordination, scalability, and outcome tracking, positioning home healthcare as a central component of modern, value-based care delivery. The worldwide population is aging while chronic diseases become more common:The aging population across developed regions such as North America, Europe, and parts of the Asia-Pacific area stands as a key driver for the home healthcare market expansion. The United Nations reports that by 2050 the number of people aged 65 years or older will reach over 1.5 billion worldwide as their population doubles. The demographic shift leads to more chronic illness cases such as cardiovascular diseases, diabetes, arthritis, dementia, and respiratory conditions that demand ongoing monitoring and long-term treatment. Home healthcare represents a better option than institutional care for many older patients because it provides high-quality treatment within their own homes where they feel safe and comfortable. The growing need for home healthcare solutions has expanded the market for in-home nursing services alongside physical therapy options and disease management programs and remote patient monitoring tools thereby integrating home healthcare into essential care processes. For Detailed Market Insights, Visit: Technological Advancements in Remote Monitoring and Telehealth:Medical technology developments have led to enhanced operational capabilities for home healthcare services. Home administration of complex treatments has become both safe and efficient due to the use of portable oxygen concentrators, mobile dialysis machines, infusion pumps, and wearable health monitors. The rapid expansion of telehealth services and digital health platforms has enabled patients to conduct virtual consultations easily while receiving continuous monitoring and making decisions based on data analysis. The importance of these technologies increased after COVID-19 because they serve to decrease hospital visits and lower exposure risks while preserving excellent care quality. The combined use of artificial intelligence (AI), Internet of Medical Things (IoMT), and cloud-based data sharing gives clinicians enhanced capabilities to manage patient outcomes proactively. These emerging solutions increase patient satisfaction and clinical success while broadening the scalability and cost-efficiency of home healthcare delivery. Cost-Effectiveness and Healthcare System Strain:Financial and logistical challenges for the global healthcare system are escalating because of increasing chronic disease burden and hospital overcrowding combined with higher treatment expenses. Home healthcare reduces financial burdens by minimizing extended hospitalizations alongside emergency room admissions and institutional facility requirements. Public and private payers experience significant cost reductions through home healthcare while maintaining high patient care standards. Home-based care models have gained support from governments and insurers who are using policy changes and financial incentives to push for their adoption. Middle-class populations in developing countries now find home healthcare services affordable and viable alternatives to pricier hospital treatments while still delivering quality medical attention. Home healthcare benefits from economic viability and practical efficiency because value-based care and patient-centred delivery models support this healthcare setting. Stay Updated on The Latest Home Healthcare Market Trends: Geographical Insights: The North American market held the largest share with 42.60%. North America maintains market dominance due to its significant elderly population along with advanced healthcare systems and high levels of consumer spending power. Future home care solutions led by government initiatives to control healthcare costs should significantly affect the market. The Asia Pacific region expects fast growth because three major factors make at-home care more convenient than hospital settings. Lack of development in healthcare infrastructure along with high hospital facility costs has triggered extensive demand for home healthcare products and services. Global Home Healthcare Market Segmentation and Geographical Insights: Based on Component, the home healthcare market is divided into, Equipment, and Services. The services segment has become a central market aspect by generating 84.21% of the total revenue share in 2023. This segment is further bifurcated into two categories: skilled home healthcare and unskilled home healthcare. Based on Indication, the home healthcare market is divided into, Cardiovascular Disorder & Hypertension, Diabetes & Kidney Disorders, Neurological & Mental Disorders, Respiratory Disease & COPD, Maternal Disorders, Mobility Disorders, Cancer, Wound Care, and Others. The neurological and mental disorder segment generated the highest revenue share in 2023 because of increasing rates of these diseases. Epilepsy, Alzheimer's and other dementias, stroke, migraine and other headaches, multiple sclerosis and Parkinson's disease cause considerable effects on brain function while affecting spine health and nerve activity. The Home Healthcare Market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Purchase Premium Copy of Global Home Healthcare Market Size and Growth Report (2024-2030) at: Key Players and Competitive Landscape: The Global Home Healthcare Market is characterized by the presence of several major players, including: B. Braun Melsungen AG Abbott Sunrise Medical 3M Healthcare Baxter International Inc. Medtronic PLC Cardinal Health Inc. F. Hoffmann-La Roche AG Air Liquide Amedisys, Inc. NxStage Medical, Inc. (Fresenius Medical Care) Arkray, Inc. BD Omron Healthcare, Inc. Drive DeVilbiss Healthcare GE Healthcare Medline Industries, Inc Koninklijke Philips N.V. Johnson & Johnson Services, Inc. Linde Healthcare Acelity (3M) Vygon Teleflex, Inc. Moog Inc. Intersurgical Ltd. Fresenius Kabi AG. Bayer HealthCare Comp14 GF Health Products, Inc. Kindred Healthcare, Inc. Almost Family, Inc. National HealthCare Corporation Chubb Fire & Security Pty Ltd Gentiva Health Services, Inc. Medco Home Healthcare, Inc. Addus Homecare Brookdale Senior Living Solutions Sunrise Carlisle, LP (Sunrise Senior Living, LLC) Genesis Healthcare, Inc. Extendicare, Inc. SONIDA SENIOR LIVING. (CAPITAL SENIOR LIVING CORPORATION) Diversicare Healthcare Services, Inc. Home Instead, Inc. Senior Care Centers of America Atria Senior Living, Inc These companies are adopting strategies such as new product launches, joint ventures, and geographical expansion to maintain their competitive edge in the market. For Region-Specific Market Data, Check Out Brief Sample Pages: Global Home Healthcare Market Recent Developments and Innovations: In July 2024: Both Allied Insurance Company and Star Health broadened their offerings to incorporate home healthcare services across more than 50 cities in India. The initiative aims to deliver healthcare solutions to customers' homes while ensuring fast and easy claims settlement. In April 2024: The U.S. Food and Drug Administration (FDA) launched its new Home as a Health Care Hub initiative. The initiative aimed to transform home environments into essential components of healthcare systems while promoting health equity throughout the United States. In May 2024: Primefocus Health represents LG Electronics' latest business venture designed to create a healthcare-delivery platform for providers that merges technological solutions with therapeutic approaches to support remote monitoring of patients and deliver new treatment options through digital applications. The system enables patients to monitor their progress while facilitating communication between patients and collecting patient data. Frequently Asked Questions (FAQs): What is the forecasted market size of the Home Healthcare Market in 2030?The forecasted market size of the Home Healthcare Market is USD 666.91 billion in 2030. Who are the leading players in the Home Healthcare Market?The key players in the Home Healthcare Market include, B. Braun Melsungen AG; Abbott; Sunrise Medical; 3M Healthcare; Baxter International Inc.; Medtronic PLC; Cardinal Health Inc; F. Hoffmann-La Roche AG; Air Liquide; Amedisys, Inc; NxStage Medical, Inc. (Fresenius Medical Care); Arkray, Inc.; Becton, Dickinson and Company; Omron Healthcare, Inc; Drive DeVilbiss Healthcare; GE Healthcare; Medline Industries, Inc; Koninklijke Philips N.V; Johnson & Johnson Services, Inc.; Linde Healthcare; Acelity (3M); Vygon; Teleflex, Inc; Moog Inc.; Intersurgical Ltd.; Fresenius Kabi AG; and GF Health Products, Inc. What are the major drivers for the Home Healthcare Market? Several key factors are driving this expansion, including the rise of cost-effective alternatives to address increasing healthcare costs has driven this growth. Which is the largest region during the forecasted period in the Home Healthcare Market?The North American market held the largest share with 42.60%. North America maintains market dominance due to its significant elderly population along with advanced healthcare systems. Which is the largest segment, by component, during the forecasted period in the Home Healthcare Market?The services segment has become a central market aspect by generating 84.21% of the total revenue share. Need A Diverse Region or Sector? Customize Research to Suit Your Requirement: Conclusion: The global home healthcare market is experiencing significant transformation driven by demographic shifts, chronic disease prevalence, and advancements in medical technology. Increasing aging populations, alongside a growing preference for in-home treatment, are accelerating the adoption of home-based care solutions. Innovations in remote monitoring, wearable devices, telehealth platforms, and mobile diagnostics are enabling healthcare providers to deliver high-quality care outside traditional clinical settings. The integration of AI-powered analytics, Internet of Medical Things (IoMT), and smart home technologies supports proactive care, real-time health tracking, and personalized treatment plans. Emphasis on cost-effective and patient-centric healthcare models is reshaping the delivery landscape, making home healthcare a vital component of modern health systems. To ensure long-term success, the sector must address regulatory challenges, data privacy concerns, and the need for robust digital infrastructure. As digital transformation continues, home healthcare stands poised to play a central role in sustainable and accessible global health solutions. The report from The Research Insights, therefore, provides several stakeholders—patients, caregivers, doctors, nurses, government agencies, insurance companies, pharmaceutical firms, medical device manufacturers, technology providers (e.g., for telehealth and remote monitoring), home healthcare service providers, and investors—with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. With projected growth to US$ 666.91 billion by 2030, the Global Home Healthcare Market represents a significant opportunity for technology startups, innovative medical device companies, software developers specializing in health tech, and new service models focusing on niche patient needs or underserved regions, can position themselves for success in this dynamic and evolving market landscape. Check out more related studies published by The Research Insights: Pediatric Home Healthcare Market: The Global Pediatric Home Healthcare Market is expected to reach at USD 65.1 billion by 2030, according to a new report by The Research Insights. It is projected to expand at a CAGR of 7.86% during the forecast period, driven by advancements in technology and an increasing demand for personalized care at home. Mobile Imaging Services Market: The Global Mobile Imaging Services Market is expected to reach at USD 2.05 billion by 2025, according to a new report by The Research Insights. It is projected to expand at a CAGR of 3.2% during the forecast period, driven by the increasing need for precision diagnostic tools has led to a surge in demand for mobile imaging services. Browse More related reports on Healthcare Industry Market Reports – About Us: The Research Insights provides thoroughly conducted research which is backed up by real-time statistics and data. Our experts are eager to help you with any information required under the sun. The key to our success is keeping abreast with the markets, industries, and ever-changing consumer trends that matter. Our market research professionals have in-depth knowledge and expertise across various domains that includes IT and Telecom, Emerging Technologies, Consumer Offerings, Manufacturing and Others. We are committed to reviewing the scope and procedure of the research studies that you select and provide you with an accurate guidance in order to assist you in taking the correct business decisions. Contact Us:If you have any queries about this report or if you would like further information, please contact us: Contact Person: Kaushik RoyE-mail: sales@ +1-312-313-8080Blog: Release: News: | Logo: View original content: SOURCE The Research Insights Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data